Arginine reduced amyloid beta aggregation in vitro and in both Drosophila and AppNL-G-F mouse models of Alzheimer’s disease, leading to fewer dense-core plaques and improved behavior. The study provides preclinical evidence that oral arginine may modulate amyloid pathology, although high dosing requirements and model limitations constrain human translation.